2L=second-line; mTNBC=metastatic triple- negative breast cancer.
*
Real-world study published in 2025 of patients diagnosed with previously untreated mTNBC (n=2004) from 2011 to 2022 at approximately 280 cancer clinics in the US. Of these patients, 51% (1030/2004) received second-line treatment.
Reference: Punie K, Kurian AW, Ntalla I, et al. Unmet need for previously untreated metastatic triple-negative breast cancer: a real-world study of patients diagnosed from 2011 to 2022 in the United States. Oncologist. 2025;30(3):oyaf034. doi:10.1093/oncolo/oyaf034
GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc., or its related companies. All other marks are the property of their respective owners.
